In a multicenter, randomized, double-blind parallel group study of patients with mild to moderate pain associated with osteoarthritis of the hip and/or knee, extended release oxymorphone, an investigational formulation of the semisynthetic opioid agonist, demonstrated superior analgesic efficacy to oxycodone CR (OxyContin®) and placebo.
The findings were presented August 21st at the 10th World Congress on Pain. In an interview, lead author Alan K. Matsumoto, MD, said the drug “may be a good therapeutic option for patients with chronic knee or hip pain, especially since opioids do not have the GI toxicity associated with NSAIDs.”
Four hundred sixty-seven patients with Kellgren-Lawrence grade II-IV osteoarthritis of the hip or knee, and index joint pain rated >40mm (VAS) and incomplete response to NSAIDs were randomized to: oxymorphone ER 40mg or 20mg every 12 hours, OxyContin 20 mg every 12 hours, or placebo. Primary outcome was change in VAS pain at week three.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!